What is MiMedx Group's gross profit margin?

What is the market's earnings forecast for MiMedx Group next quarter?

What does MiMedx Group do and what are its main business segments?

Did MiMedx Group beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for MiMedx Group year over year?

What were the key takeaways from MiMedx Group’s earnings call?

What is MiMedx Group's latest dividend and current dividend yield?

What factors drove the changes in MiMedx Group's revenue and profit?

- **Record Q3 Performance**: $114M revenue (+35% YoY), $35M adjusted EBITDA, and $124M net cash highlight strong execution.
- **Surgical Growth Engine**: 26% YoY expansion driven by AMNIOFIX and HELIOGEN, with $500M+ TAM in colorectal surgery.
- **Wound Care Resilience**: 40% YoY growth despite reimbursement headwinds, supported by new products like CELERA and EMERGE.
- **Cash Powerhouse**: $150M+ net cash by year-end to fund growth and capitalize on 2026 Medicare reforms.
- **Strategic Focus**: Surgical market expansion, customer intimacy programs (e.g., MiMedx Connect), and evidence-based innovation.

**【CEO Opening Remarks】**
- Q3 2025 revenue reached $114 million, up 35% YoY, with record adjusted EBITDA of $35 million (31% of net sales). Full-year guidance raised to mid- to high teens revenue growth and mid-20s EBITDA margin.
- Surgical segment grew 26% YoY, driven by AMNIOFIX and HELIOGEN. Wound segment grew 40% YoY, boosted by new products like CELERA and EMERGE.
- Launched EPIXPRESS, a fenestrated allograft for post-acute wound care, with positive early feedback.
- Completed interim analysis of EPIEFFECT RCT, with favorable results to be presented at Tissue Repair Evidence Summit.
- Net cash position of $124 million, expected to exceed $150 million by year-end.

**【CFO Financial Review】**
- GAAP net income: $17 million ($0.11 EPS) vs. $8 million ($0.05 EPS) YoY. Adjusted net income: $23 million ($0.15 EPS) vs. $10 million ($0.07 EPS) YoY.
- Gross margin: 84% (GAAP) / 88% (non-GAAP), up 540bps YoY due to product mix and cost efficiency.
- Operating expenses: Sales & marketing at 47% of sales (vs. 50% YoY), G&A at 13% (vs. 14% YoY), R&D at 3% (up $0.8 million YoY).
- Free cash flow: $29 million Q3, record for the company.

**【Q&A Highlights】**
- **Wound vs. Surgical Growth**: Wound franchise grew 40% Q3, Surgical 26%. Q4 growth may face tougher comps but surgical momentum expected to continue.
- **Reimbursement Preparedness**: Company confident in ability to outperform post-2026 Medicare reforms, with $150+ million net cash to capitalize on market share gains.
- **M&A Strategy**: Focused on surgical assets with strategic fit, avoiding wound care due to reimbursement uncertainty.
- **Product Adoption**: HELIOGEN adoption increasing sequentially; AXIOFILL stable despite legal challenges.
- **LCD Submission**: EPIEFFECT interim analysis data submitted for Medicare coverage, with final rules expected in November.

MiMedx Group, Inc. (MDXG) Q3 2025 Earnings Call Transcript

- **Q2 Growth Milestones**: 13% YoY revenue rise to $99M, record $24M EBITDA, and $119M cash. Surgical segment up 15% YoY.
- **Strategic Expansion**: New products (EMERGE, VHT) and focus on surgical markets drive diversification. 
- **Reform Resilience**: Confident in post-reform share gains via superior evidence base and fixed pricing model. 
- **Financial Strength**: Free cash flow $14M, ending cash >$150M, and 2025 EBITDA margin >20%.

**【CEO Summary Section】**
- **Record Q2 Performance**: Net sales of $99 million (+13% YoY), highest quarterly revenue and adjusted EBITDA ($24 million, 25% of net sales). Surgical segment grew 15% YoY, driven by AMNIOEFFECT and HELIOGEN adoption.
- **Strategic Priorities**: 
  1. **Product Diversification**: Launched EMERGE and expanded collaboration with Vaporox for VHT device (80%+ wound healing rate in trials). 
  2. **Surgical Market Expansion**: AMNIOEFFECT sales growth reflects early-stage adoption in surgical procedures. 
  3. **Customer Intimacy**: MiMedx Connect adoption improves workflow and customer retention.
- **Medicare Reform Readiness**: Welcomes CMS's fixed pricing model ($125.38/sq cm) and WISeR model to curb fraud. Expects rational market with focus on product efficacy.
- **Guidance Update**: Full-year revenue growth raised to low double digits, adjusted EBITDA margin >20%, ending cash >$150 million.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Wound ($64M, +12% YoY) and Surgical ($34M, +15% YoY). Non-GAAP gross margin 84%, flat YoY. 
- **Expense Management**: 
  - Sales & Marketing: $48M (+14% YoY) due to higher commissions. Full-year ~50-51% of sales. 
  - G&A: $16M (+14% YoY). Full-year ~13% of sales. 
  - R&D: $3M (+11% YoY) for EPIEFFECT RCT. Full-year ~4% of sales. 
- **Liquidity**: Cash $119M (+$12M QoQ), free cash flow $14M. Net cash position $100M, up from $88M last quarter.

**【Q&A Highlights】**
- **Market Size Post-Reform**: CEO estimates reduced market size but confident in share gains via product efficacy. Current ASPs near proposed $125/sq cm, requiring modest share pickup.
- **Vaporox Collaboration**: Pilot program for VHT device (510(k)-cleared, 80%+ healing rate) to complement wound care portfolio. No material contribution expected until 2026.
- **Inventory Management**: Monitoring pre-reform stocking; experienced in ASP methodology-driven inventory management. 
- **LCD Implementation**: Advocating for higher application fees for mobile wound care providers to reduce reliance on product margins.

MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript

- **Resilient Q1 Growth**: 4% net sales growth vs. 18% prior year, driven by surgical (+16%) and AMNIOEFFECT (+22%). 
- **Cash Strength**: $106M cash balance (+$2M QoQ), net cash up $59M YoY to $88M. 
- **Reimbursement Risk Management**: Added CELERA allograft to mitigate 25% ASP-exposed business, while advocating for CMS pricing reform. 
- **Surgical Momentum**: HELIOGEN gaining traction; no ASP exposure for core surgical portfolio. 
- **Guidance Confirmed**: High single-digit revenue growth and >20% EBITDA margin for 2025. 


**【CEO Opening Remarks】**
- Q1 2025 net sales grew 4% YoY to $88 million, despite one fewer business day and a tough comp from Q1 2024 (18% growth). 
- Surgical business drove 16% growth, led by AMNIOEFFECT (+22%) and HELIOGEN (sequential gains). 
- Adjusted EBITDA of $17 million (20% of net sales) and cash balance increased to $106 million. 
- Reaffirmed full-year guidance: high single-digit revenue growth and >20% adjusted EBITDA margin. 

**【CFO Financial Review】**
- GAAP net income: $7 million ($0.05 EPS) vs. $9 million ($0.06 EPS) prior year. 
- Non-GAAP adjusted gross margin: 84% (down 100bps YoY due to product mix). 
- Sales & marketing expenses: $47 million (+7% YoY) due to higher commissions and comp plan changes. 
- R&D expenses: $3 million (+17% YoY) for EPIEFFECT RCT and pipeline products. 
- Free cash flow: $5 million (flat YoY). 

**【Q&A Key Highlights】**
1. **Reimbursement Environment**: 
   - Medicare LCD delay to 2026 leaves 25% of business exposed to ASP pricing distortions. 
   - Added third-party allograft CELERA to retain share, but cautious on contribution. 
   - Advocating for CMS action on physician fee schedule pricing methodology. 
2. **Surgical Growth Drivers**: 
   - HELIOGEN growing sequentially from low base. 
   - AMNIOEFFECT and AMNIOFIX benefiting from no ASP exposure. 
3. **Cash Position**: 
   - Net cash balance up $59 million YoY to $88 million, enabling M&A and R&D investments. 
4. **Japan Market**: 
   - EPIFIX growing but not material; on track with expectations. 
5. **Fraud Waste & Abuse**: 
   - CMS estimates $1 billion/month in suspect claims; MIMEDX products represent <1% of spend. 


MiMedx (MDXG)-30 Apr 25-2025 Q1 Earnings call transcript

- **Strong 2024 Performance**: 9% revenue growth to $349M, $76M adjusted EBITDA, and $104M cash balance.
- **2025 Guidance**: High single-digit revenue growth, >20% EBITDA margin, with potential for acceleration post-LCD implementation.
- **Key Drivers**: EFFECT product line expansion, Japan market tripling, and HELIOGEN early launch.
- **Risk & Opportunity**: Medicare LCD disruption in private office, but MiMedx positioned to gain share through covered products and clinical evidence.
- **Financial Health**: Free cash flow of $19M in Q4, 82% gross margin, and $86M net cash position.


**【CEO Opening Remarks】**
- Full-year 2024 revenue grew 9% to $349 million, driven by 7% Q4 growth to $93 million.
- Adjusted EBITDA of $20 million (21% of sales) in Q4, up $18 million annually to $76 million (22% of sales) for the year.
- Cash balance increased by $16 million in Q4 to $104 million.
- Key strategic priorities: product innovation (e.g., HELIOGEN launch), surgical market expansion, and customer intimacy programs.
- 2025 outlook: high single-digit revenue growth, >20% EBITDA margin, with potential for low double-digit growth post-LCD implementation.

**【CFO Financial Review】**
- Q4 gross profit of $76 million (82% margin), with non-GAAP margin flat year-over-year at 84%.
- SG&A expenses rose 13% to $61 million due to higher commissions and sales investments.
- R&D expenses increased 38% to $3 million for clinical trials and pipeline development.
- Free cash flow of $19 million in Q4, up 97% annually, driving net cash to $86 million.
- 2025 guidance: high single-digit revenue growth, >20% EBITDA margin, with Q1 typically the lowest quarter.

**【Q&A Highlights】**
- **Wound Care Growth**: Driven by EFFECT products, EpiFix expansion, and Japan market tripling in 2024.
- **Sales Force Stability**: Team restored to full strength post-mid-2024 turnover, with no further delays expected for LCD implementation.
- **HELIOGEN Outlook**: Early launch phase with potential 2025 contribution, but no specific revenue targets yet.
- **LCD Impact**: Anticipated disruption in private office market, with MiMedx well-positioned to gain share through covered products and clinical evidence.
- **Legal Matters**: Active in defending IP (e.g., Surgenex lawsuit) and challenging FDA classifications (AXIOFIL case), with progress in regulatory clarity.


MiMedx (MDXG)-26 Feb 25-2024 Q4 Earnings call transcript

MiMedx (MDXG)-30 Oct 24-2024 Q3 Earnings call transcript

Mimedx (MDXG)-31 Jul 24-2024 Q2 Earnings call transcript

Mimedx (MDXG)-30 Apr 24-2024 Q1 Earnings call transcript

Mimedx (MDXG)-28 Feb 24-2023 Q4 Earnings call transcript

Mimedx (MDXG)-30 Oct 23-2023 Q3 Earnings call transcript

- **Revenue Growth**: Q2 2023 net sales of $81.3 million (+21.5% YoY), highest in nearly four years.
- **Profitability**: Adjusted EBITDA of $14.1 million (17.4% of sales), up from a loss of $1 million YoY.
- **Japan Expansion**: Early-stage adoption of first-of-kind product, with KOLs reporting success in complex wounds.
- **Financial Health**: $68.7 million cash balance, targeting $90M+ by year-end for growth opportunities.
- **Strategic Shift**: Suspension of Knee OA trial frees $15M in EBITDA, refocusing on core Wound & Surgical markets.

**【CEO Summary Section】**
- Q2 2023 net sales: $81.3 million (+21.5% YoY), highest in nearly four years.
- Gross profit margin: 83.3% (up 100bps YoY), driven by product mix and operational efficiency.
- Adjusted EBITDA: $14.1 million (17.4% of sales), up from a loss of $1 million YoY.
- Wound & Surgical segment contribution margin: 34.3% (vs. 21.5% YoY), exceeding 30% target.
- Japan market progress: increased interest in first-of-kind product, adoption expected to ramp in coming quarters.
- Strategic pivot: suspended Knee Osteoarthritis trial to focus on core markets, freeing $15M in EBITDA.
- Full year 2023 guidance raised to mid- to high-teens revenue growth.
- Cash balance: $68.7 million (up $7.5M QoQ), targeting $90M+ by year-end.

**【CFO Financial Commentary】**
- GAAP net income: $1.2 million (vs. -$10.9M YoY).
- R&D expenses: $8.5 million (+$3M YoY), driven by clinical trial costs.
- Investigation expenses: $1 million (down from $3.2M YoY).
- Restructuring costs: $3.3 million (related to Regen Medicine wind-down).
- Corporate G&A: 16.5% of sales (vs. 25.6% YoY), below 20% target.
- Wound & Surgical net sales: $80.5 million (+21.7% YoY), 99% of total revenue.
- Japan market: early-stage development, no meaningful contribution yet.

**【Q&A Key Highlights】**
- **Growth Drivers**: Surgical site sales +17% YoY, private office +25% YoY. New product launches (Q2 2022) driving momentum.
- **Japan Market**: 11 key opinion leaders trained, complex wound cases showing success. Reimbursement framework under development.
- **R&D Outlook**: $4-5M annualized spend on Knee OA trial eliminated. Future R&D focused on product line extensions.
- **Share Repurchases**: Series B preferred shares may convert to ~31M common shares if price >$7.7 for 20 days.
- **Acquisition Strategy**: $90M+ cash by year-end provides flexibility for inorganic growth opportunities.
- **Expense Management**: Wound & Surgical contribution margin >30%, G&A <20% of sales, both ahead of year-end goals.

MDXG

MDXG fundamentals

Earnings Call

You can ask Aime